Refanezumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameRefanezumab
Drug Alias Namerefanezumabum瑞法奈珠单抗瑞伐奈组单抗GSK-249320249320 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionMyelin-associated glycoprotein inhibitors
TargetsMyelin-associated glycoprotein
Therapy Area/IndicationsStroke
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsStroke

Other Information

ATC CodeN/A
Related LinksWikipedia